New isogenic cell models created by CRISPR genome editing for drug discovery
The recent development of the CRISPR/Cas9 system provides a revolutionary gene-editing technology for basic research in biology and for development of targeted cancer therapies. In addition to enabling the identification of novel drug targets through functional screening, CRISPR/Cas9 facilitates the creation of disease models for drug discovery and development.
In this webinar, ATCC experts will address how ATCC utilized this advanced technology to create novel human cell models that contain disease-relevant point mutations and gene rearrangements. In addition, we will introduce a new type of BRAF inhibitor-resistant cell line that was created by using CRISPR/Cas9 to insert the NRAS Q61K mutation. These human isogenic lines provide useful disease models for the identification and validation of new therapeutics.
